Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0003613090

MOBERG PHARMA AB (PUBL) (MOB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Moberg Pharma publ : NOMINATION COMMITTEE APPOINTED

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 01:59pm CEST

Moberg Pharma's Nomination Committee ahead of the 2018 Annual General Meeting comprises:

  • Thomas Eklund, Chairman of the Board
  • Gillis Cullin, appointed by Östersjöstiftelsen
  • Fredrik Persson, appointed by Zimbrine Holding
  • Anders Rodebjer, appointed by Wolco Invest

Together, the Nomination Committee represents 25.3 percent of the shares in Moberg Pharma as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2018 Annual General Meeting will be held in Stockholm on May 15.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to [email protected] by 31 December 2017.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on November 10th, 2017.

For additional information, please contact:
Peter Wolpert, CEO, Phone: +1 908 432 22 03 (US), +46 707 35 71 35 (SE), E-mail: [email protected]
Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: [email protected]

About Moberg Pharma, www.mobergpharma.comMoberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Moberg Pharma AB published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 12:58:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MOBERG PHARMA AB (PUBL)
06/29MOBERG PHARMA PUBL : New number of shares and votes in Moberg Pharma AB (publ)
AQ
06/20MOBERG PHARMA PUBL : Addition to Moberg Pharma’s management team
PU
06/20MOBERG PHARMA PUBL : Addition to Moberg Pharma's management team
AQ
05/25MOBERG PHARMA PUBL : The board of directors exercises authorizations to issue an..
AQ
05/15MOBERG PHARMA PUBL : Bulletin from Moberg Pharma’s AGM 2018
PU
05/15MOBERG PHARMA PUBL : Bulletin from Moberg Pharma's AGM 2018
AQ
05/10MOBERG PHARMA PUBL : Patent Issued for Pharmaceutical Compositions Comprising a ..
AQ
05/08MOBERG PHARMA AB : Interim report January - March 2018
AQ
05/02MOBERG PHARMA PUBL : U.S. patent granted for BUPI
AQ
04/27MOBERG PHARMA PUBL : completes divestment of Balmex® for $4.25 million
AQ
More news
News from SeekingAlpha
05/08Moberg Derma AB reports Q1 results 
02/13Moberg Derma AB reports Q4 results 
2017Moberg Pharma (MBGRF) Presents At Pareto Securities' 8th Annual Health Care S.. 
Financials ( SEK)
Sales 2018 385 M
EBIT 2018 54,7 M
Net income 2018 2,77 M
Debt 2018 485 M
Yield 2018 -
P/E ratio 2018 237,81
P/E ratio 2019 237,81
EV / Sales 2018 3,01x
EV / Sales 2019 2,96x
Capitalization 674 M
Chart MOBERG PHARMA AB (PUBL)
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MOB | SE0003613090 | 4-Traders
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus
Number of Analysts 2
Average target price 39,8  SEK
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Peter Gunnar Maurits Wolpert Chief Executive Officer
Thomas Lennart Eklund Chairman
Anna Ljung Chief Financial Officer
Kjell Rensfeldt Chief Medical Officer, VP-Research & Development
Geert Cauwenbergh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MOBERG PHARMA AB (PUBL)37.36%76
JOHNSON & JOHNSON-10.76%337 763
PFIZER3.20%219 534
NOVARTIS-5.10%201 464
ROCHE HOLDING LTD.-5.88%201 132
MERCK AND COMPANY11.12%169 193